Cargando…

Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH)

In recent years, much progress has been made in understanding the mechanisms of bone growth and development over a lifespan, including the crosstalk between muscle and bone, to achieve optimal structure and function. While there have been significant advances in understanding how to help improve and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glorieux, Francis H., Bonewald, Lynda F., Harvey, Nicholas C., van der Meulen, Marjolein C. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802511/ https://www.ncbi.nlm.nih.gov/pubmed/35101067 http://dx.doi.org/10.1186/s13023-021-02156-x

Ejemplares similares

X-linked Hypophosphatemia (XLH) Mimicking Rheumatic Disease
por: Takase, Ryosuke, et al.
Publicado: (2020)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
por: Schindeler, Aaron, et al.
Publicado: (2020)

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
por: Brener, Avivit, et al.
Publicado: (2021)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
por: Brener, Rafi, et al.
Publicado: (2022)

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-Linked Hypophosphatemia (XLH)
por: Ross, Ryan, et al.
Publicado: (2023)

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)
por: Carpenter, Kelsey A., et al.
Publicado: (2023)

The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
por: Ariceta, Gema, et al.
Publicado: (2023)

SUN-363 Hypophosphatemia Gene Panel Sponsored Program: A High Yield Of Molecular Diagnoses from Clinically Confirmed XLH and Suspected XLH/ Genetic Hypophosphatemia
por: Miller, Nicole, et al.
Publicado: (2020)

Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study
por: Mindler, Gabriel T., et al.
Publicado: (2022)

Novel PHEX gene locus‐specific database: Comprehensive characterization of vast number of variants associated with X‐linked hypophosphatemia (XLH)
por: Sarafrazi, Soodabeh, et al.
Publicado: (2021)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)
por: Seefried, Lothar, et al.
Publicado: (2023)

Hypophosphatemia Gene Panel Sponsored Program: A High Yield of Molecular Diagnoses from Clinically Confirmed XLH and Suspected Genetic Hypophosphatemia
por: Dahir, Kathryn, et al.
Publicado: (2021)

OR13-3 Hypophosphatemia Gene Panel Sponsored Program: A High Yield of Molecular Diagnoses from Clinically Confirmed XLH and Suspected Genetic Hypophosphatemia
por: Japalaghi, Omid K, et al.
Publicado: (2022)

Musculoskeletal Features in Adults With X-linked Hypophosphatemia: An Analysis of Clinical Trial and Survey Data
por: Javaid, Muhammad Kassim, et al.
Publicado: (2021)

Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
por: Kamenicky, Peter, et al.
Publicado: (2023)

Serum Levels of Lipocalin Are Lower in Adolescents With X-Linked Hypophosphatemia
por: Simpson, Christine A, et al.
Publicado: (2021)

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
por: Ward, Leanne M, et al.
Publicado: (2022)

X-Linked Hypophosphatemia: A New Era in Management
por: Dahir, Kathryn, et al.
Publicado: (2020)

Dental management of patients with X-linked hypophosphatemia
por: Lee, Bin-Na, et al.
Publicado: (2017)

Growth Curves for Children with X-linked Hypophosphatemia
por: Mao, Meng, et al.
Publicado: (2020)

Enthesopathy, Osteoarthritis, and Mobility in X-linked Hypophosphatemia
por: Imel, Erik A
Publicado: (2020)

Genotype and Phenotype Analysis in X-Linked Hypophosphatemia
por: Park, Peong Gang, et al.
Publicado: (2021)

Impact of X-Linked Hypophosphatemia on Muscle Symptoms
por: Romagnoli, Cecilia, et al.
Publicado: (2022)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

Impaired 1,25 dihydroxyvitamin D(3) action and hypophosphatemia underlie the altered lacuno-canalicular remodeling observed in the Hyp mouse model of XLH
por: Yuan, Ye, et al.
Publicado: (2021)

Decreased Compressional Sound Velocity Is an Indicator for Compromised Bone Stiffness in X-Linked Hypophosphatemic Rickets (XLH)
por: Raimann, Adalbert, et al.
Publicado: (2020)

The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study
por: Padidela, Raja, et al.
Publicado: (2020)

Autism and X-linked hypophosphatemia: A possible association?
por: Joël, Vermeersch, et al.
Publicado: (2010)

SUN-526 Prevalence of Hyperparathyroidism in X-Linked Hypophosphatemia
por: DeLacey, Sean, et al.
Publicado: (2019)

Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
por: Gadion, Margaux, et al.
Publicado: (2022)

Craniosynostosis in Patients With X‐Linked Hypophosphatemia: A Review
por: Munns, Craig F, et al.
Publicado: (2023)

Health-related quality of life of X-linked hypophosphatemia in Spain
por: Yanes, M. I. Luis, et al.
Publicado: (2022)

Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries
por: Al Juraibah, Fahad, et al.
Publicado: (2021)

Lower Limb Deformity and Gait Deviations Among Adolescents and Adults With X-Linked Hypophosphatemia
por: Mindler, Gabriel T., et al.
Publicado: (2021)

Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level
por: Imel, Erik A, et al.
Publicado: (2023)

Prevalence and clinical characteristics of X-linked hypophosphatemia in Paraná, southern Brazil
por: Moreira, Carolina Aguiar, et al.
Publicado: (2020)

OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program
por: Carpenter, Thomas, et al.
Publicado: (2022)

Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia
por: Zhukouskaya, Volha V, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vl66tdbao9c2bjnhsum2joggic